Drug Type Small molecule drug |
Synonyms ALBUTEROL, ALBUTEROL SULFATE, Salbutamol + [53] |
Target |
Action agonists |
Mechanism β2-adrenergic receptor agonists(Beta-2 adrenergic receptor agonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization- |
Drug Highest PhaseApproved |
First Approval Date Japan (13 Jan 1973), |
RegulationOrphan Drug (United States) |
Molecular FormulaC13H23NO7S |
InChIKeyOVICLFZZVQVVFT-UHFFFAOYSA-N |
CAS Registry51022-70-9 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | Salbutamol sulfate |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Asthma, Exercise-Induced | United States | 01 May 1981 | |
Bronchial Spasm | United States | 01 May 1981 | |
Airway Obstruction | Japan | 13 Jan 1973 | |
Asthma | Japan | 13 Jan 1973 | |
Bronchitis | Japan | 13 Jan 1973 | |
Pulmonary Emphysema | Japan | 13 Jan 1973 | |
Pulmonary Tuberculosis | Japan | 13 Jan 1973 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Acute asthma | NDA/BLA | Canada | - | |
Persistent asthma | Phase 3 | United States | 01 Oct 2010 | |
Childhood asthma | Phase 3 | United States | 10 Jun 2006 | |
Pulmonary Disease, Chronic Obstructive | Phase 3 | United States | 01 Sep 2004 | |
Pulmonary Disease, Chronic Obstructive | Phase 3 | Puerto Rico | 01 Sep 2004 | |
Idiopathic Pulmonary Fibrosis | Phase 1 | United Kingdom | 01 Apr 2012 | |
airway disease | Phase 1 | - | 01 Mar 2009 | |
Mild asthma | Clinical | India | 15 Aug 2022 | |
Mild asthma | Clinical | Taiwan Province | 15 Aug 2022 | |
Asthma chronic | Clinical | United States | 01 Nov 2006 |
Phase 3 | 2,421 | uxtcyxzced(qlkuuezdfc) = oyxhwuzqct nayodscgni (vhsmcaehln ) View more | Positive | 19 May 2025 | |||
uxtcyxzced(qlkuuezdfc) = szrhvtldaj nayodscgni (vhsmcaehln ) View more | |||||||
Phase 3 | 2,516 | Albuterol-Budesonide | ijauyjjptf(aikhdrsfmr) = rrlzfukfgg jaeqmoqwaj (gdwicmcalp ) | Positive | 19 May 2025 | ||
ijauyjjptf(aikhdrsfmr) = umhzdikgod jaeqmoqwaj (gdwicmcalp ) | |||||||
Phase 3 | Airway Obstruction fractional exhaled nitric oxide | 84 | Albuterol-Budesonide 180/160 µg | kanluiettp(ajxlycrdjs) = rloukbppbw nnnjqbpwnz (psfgsxuhvg ) View more | Positive | 16 May 2025 | |
Not Applicable | - | 6 | qsrkirfudn(enxauiqhot) = dboonelyfi ngbjppdpqj (hkazfrdtem, 79) | Positive | 16 May 2025 | ||
qsrkirfudn(enxauiqhot) = cemtmybnna ngbjppdpqj (hkazfrdtem, 73) | |||||||
Not Applicable | - | - | rsqeakqkix(cxhpekoqqe) = cpfzhfphak aavijyteld (nraqiqfool ) | - | 16 May 2025 | ||
rsqeakqkix(cxhpekoqqe) = zmswnimuds aavijyteld (nraqiqfool ) | |||||||
Not Applicable | - | Albuterol Nebulization | jqkhtnzcna(odyfugqoca) = aobwcxbbkj qdhjmqumgi (lwjwntxofa ) View more | Negative | 16 May 2025 | ||
Not Applicable | - | - | AIRSUPRA® (albuterol 90µg/budesonide 80µg) MDI alone | sydanhfdmq(akhaxjpfxy) = wazpnrbkwh blhynepnpv (rlbcneyeng, 1.7) View more | - | 16 May 2025 | |
AIRSUPRA® (albuterol 90µg/budesonide 80µg) MDI + AeroChamber2go | sydanhfdmq(akhaxjpfxy) = vmmiqxjoui blhynepnpv (rlbcneyeng, 1.7) View more | ||||||
Phase 4 | 42 | (SYMBICORT as Maintenance and Reliever Treatment) | fiyovjeipm(ujffcmqxqq) = yerrvbfdyz sshjmkbtvl (qyqfhjmalo, rtvfitcuhy - hjvtddwpqw) View more | - | 22 Jan 2025 | ||
(SYMBICORT as Maintenance, Salbutamol as Reliever Treatment) | fiyovjeipm(ujffcmqxqq) = trznbecpux sshjmkbtvl (qyqfhjmalo, jydycqfxya - jvmgelnequ) View more | ||||||
Phase 4 | 170 | (Treatment Reduction) | iimhaipkoh = fjqclyyjaq lcrmvrjypv (npdlztfdaf, slvgmvaypx - dnatcukrsk) View more | - | 09 Jan 2025 | ||
(Reference) | duxiekfhuo(gpgbeflajj) = zodczqbevf prvcblvffd (fhfbncrtvj, 0.0677) View more | ||||||
Phase 4 | 100 | zwqznfirjk = poitfqpiqb nxqwqxhevx (twxukyralz, pzheqojext - pacgoqdcel) View more | - | 10 Dec 2024 |